Evidence map›Paper›PMID 35701753›Full record

ArticleBMC ophthalmology2022

Mobility test to assess functional vision in dark-adapted patients with Leber congenital amaurosis.

Alejandro J Roman, Artur V Cideciyan, Vivian Wu, Abraham A Mascio, Arun K Krishnan, Alexandra V Garafalo, Samuel G Jacobson

Open access · goldAbstract read
In one paragraph

Article in BMC ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Review
  5. Observational
  6. Article
  7. Article
  8. [Gene therapy in ophthalmology].Die Ophthalmologie · 2023
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alejandro J RomanScheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, 51 North 39th St, PA, 19104, Philadelphia, USA.ORCID http://orcid.org/0000-0001-7368-3007
Artur V CideciyanScheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, 51 North 39th St, PA, 19104, Philadelphia, USA.ORCID http://orcid.org/0000-0002-2018-0905
Vivian WuScheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, 51 North 39th St, PA, 19104, Philadelphia, USA.
Abraham A MascioScheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, 51 North 39th St, PA, 19104, Philadelphia, USA.
Arun K KrishnanScheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, 51 North 39th St, PA, 19104, Philadelphia, USA.
Alexandra V GarafaloScheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, 51 North 39th St, PA, 19104, Philadelphia, USA.
Samuel G JacobsonScheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, 51 North 39th St, PA, 19104, Philadelphia, USA. Sjacobso@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0003-2122-169X
Penn Presbyterian Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInherited retinal degenerations (IRDs) affect daylight and night vision to different degrees. In the current work, we devise a method to quantify mobility under dark-adapted conditions in patients with severe childhood blindness due to Leber congenital amaurosis (LCA). Mobility thresholds from two different LCA genotypes are compared to dark-adapted vision measurements using the full-field stimulus test (FST), a conventional desktop outcome measure of rod vision.

methodsA device consisting of vertical LED strips on a plane resembling a beaded curtain was programmed to produce a rectangular pattern target defining a 'door' of varying luminance that could appear at one of three positions. Mobility performance was evaluated by letting the subject walk from a fixed starting position ~ 4 m away from the device with instructions to touch the door. Success was defined as the subject touching within the 'door' area. Ten runs were performed and the process was repeated for different levels of luminance. Tests were performed monocularly in dark-adapted and dilated eyes. Results from LCA patients with the GUCY2D and CEP290 genotypes and normal subjects were analyzed using logistic regression to estimate the mobility threshold for successful navigation. The relation of thresholds for mobility, FST and visual acuity were quantified using linear regression.

resultsNormal subjects had mobility thresholds near limits of dark-adapted rod vision. GUCY2D-LCA patients had a wide range of mobility thresholds from within 1 log of normal to greater than 8 log abnormal. CEP290-LCA patients had abnormal mobility thresholds that were between 5 and 6 log from normal. Sensitivity loss estimates using FST related linearly to the mobility thresholds which were not correlated with visual acuity.

conclusionsThe mobility task we developed can quantify functional vision in severely disabled patients with LCA. Taken together with other outcome measures of rod and cone photoreceptor-mediated vision, dark-adapted functional vision should provide a more complete understanding of the natural history and effects of treatment in patients with LCA.

Indexed as

Leber Congenital AmaurosisRetinal DegenerationAntigens, NeoplasmCell Cycle ProteinsChildCytoskeletal ProteinsDark AdaptationHumansMutationRetinal Cone Photoreceptor CellsVision, OcularAntigens, NeoplasmCell Cycle ProteinsCep290 protein, humanCytoskeletal ProteinsChildhood blindnessCone visionInherited retinal degenerationsLow visionOutcome measuresRod vision

Identifiers

PMID35701753
PMCPMC9195222
OpenAlexW4282917449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.